The downgrade from Overweight to Neutral by Cantor Fitzgerald indicates a less optimistic outlook for Chinook Therapeutics. This change in rating, along with the announcement of a $40 price target, could lead to a short-term negative impact on the stock price as investors may adjust their positions based on the new rating.